Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

References

• Cox NJ, Fukuda K. Influenza. Infect. Dis. Clin. North Am.12(1), 27–38 (1998).
   PubMed Web of Science ®Google Scholar
• Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev.56(1), 152–179 (1992).
   PubMedGoogle Scholar
• Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med.360(25), 2605–2615 (2009).
   PubMed Web of Science ®Google Scholar
• Smith GJ, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature459(7250), 1122–1125 (2009).
   PubMed Web of Science ®Google Scholar
• Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science325(5937), 197–201 (2009).
   PubMed Web of Science ®Google Scholar
• Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost–effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann. Intern. Med.151(12), 840–853 (2009).
   PubMed Web of Science ®Google Scholar
• Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA103(15), 5935–5940 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med.361(7), 680–689 (2009).
   PubMed Web of Science ®Google Scholar
• Chan M. World now at the start of 2009 influenza pandemic: World Health Organization, Geneva, Switzerland (2009).
   Google Scholar
• Kilbourne ED. Influenza pandemics of the 20th Century. Emerg. Infect. Dis.12(1), 9–14 (2006).
   PubMed Web of Science ®Google Scholar
• Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull. Hist. Med.65(1), 4–21 (1991).
   PubMed Web of Science ®Google Scholar
• Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 ‘Spanish’ influenza pandemic. Bull. Hist. Med.76(1), 105–115 (2002).
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis.12(1), 15–22 (2006).
   PubMed Web of Science ®Google Scholar
• Guleria R, Kumar J, Mohan A, Wig N. Influenza A: from highly pathogenic H5N1 to pandemic 2009 H1N1. Epidemiology and clinical features. Indian J. Microbiol.49, 315–319 (2009).
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Lochindarat S, Srisan P et al. Cases of influenza A (H5N1) – Thailand, 2004. MMWR Morb. Mortal. Wkly Rep.53(5), 100–103 (2004).
   PubMedGoogle Scholar
• World Health Organization. H5N1 avian influenza: first steps towards development of a human vaccine. Wkly Epidemiol. Rec.80(33), 277–278 (2005).
   PubMedGoogle Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292(11), 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med.362(18), 1708–1719 (2010).
   PubMed Web of Science ®Google Scholar
• Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet375(9270), 1100–1108 (2010).
   PubMed Web of Science ®Google Scholar
• Donaldson LJ, Rutter PD, Ellis BM et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. Br. Med. J.339, b5213 (2009).
   PubMed Web of Science ®Google Scholar
• Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet374(9707), 2072–2079 (2009).
   PubMed Web of Science ®Google Scholar
• Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary estimates of mortality and years of life lost associated with the 2009 A/H1N1 pandemic in the US and comparison with past influenza seasons. PLoS Curr. InfluenzaRRN1153 (2010).
   Google Scholar
• Bishop JF, Murnane MP, Owen R. Australia’s winter with the 2009 pandemic influenza A (H1N1) virus. N. Engl. J. Med.361(27), 2591–2594 (2009).
   PubMed Web of Science ®Google Scholar
• Kuehn BM. CDC names H1N1 vaccine priority groups. JAMA302(11), 1157–1158 (2009).
   PubMed Web of Science ®Google Scholar
• Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N. Engl. J. Med.361(20), 1935–1944 (2009).
   PubMed Web of Science ®Google Scholar
• Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med.361(20), 1945–1952 (2009).
   PubMed Web of Science ®Google Scholar
• Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection – United States, April–August 2009. MMWR Morb. Mortal. Wkly Rep.58(34), 941–947 (2009).
   PubMedGoogle Scholar
• Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev.2, CD004879 (2008).
   PubMed Web of Science ®Google Scholar
• Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet367(9523), 1657–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet375(9708), 55–66 (2009).
   Google Scholar
• Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled Phase 2 trials. Lancet375(9708), 41–48 (2009).
   PubMed Web of Science ®Google Scholar
• Nolan T, McVernon J, Skeljo M et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA303(1), 37–46 (2010).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine28(3), 849–857 (2010).
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months–12 years: open label, randomised, parallel group, multicentre study. Br. Med. J.340, c2649 (2010).
   PubMed Web of Science ®Google Scholar
• Carmona A, Omenaca F, Tejedor JC et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine28(36), 5837–5844 (2010).
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine28(7), 1740–1745 (2010).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine27(45), 6284–6290 (2009).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Neuzil KM. 2009 influenza A(H1N1) monovalent vaccines for children. JAMA303(1), 73–74 (2010).
   PubMed Web of Science ®Google Scholar
• Collin N, de Radigues X. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine27(38), 5184–5186 (2009).
   PubMed Web of Science ®Google Scholar
• Pandemic influenza A (H1N1) 2009 virus vaccine – conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. Wkly Epidemiol. Rec.84(49), 505–508 (2009).
   PubMedGoogle Scholar
• Dalton I. (H1N1) Swine Flu Influenza: Phase Two of the Vaccination Programme; Children Over 6 Months and Under 5 Years. Department of Health, London, UK (2009).
   Google Scholar
• GlaxoSmithKline. Real-life experience with the H1N1 2009 pandemic: new data on vaccines and antivirals. Presented at: Options for the Control of Influenza VII. Hong Kong SAR, China, 3–7 September 2010.
   Google Scholar
• EMEA. CHMP Assessment Report for Pandemrix. European Medicines Agency (2009).
   Google Scholar
• EMEA. European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009. European Medicines Agency (2009).
   Google Scholar
• WHO. Summary of available candidate vaccine viruses for development of Pandemic (H1N1) 2009 virus vaccines. World Health Organization, Geneva, Switzerland (2009).
   Google Scholar
• Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine26(26), 3209–3222 (2008).
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine27(49), 6959–6965 (2009).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet370(9587), 580–589 (2007).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One3(2), e1665 (2008).
   PubMed Web of Science ®Google Scholar
• Chu DW, Hwang SJ, Lim FS et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a Phase III study in a large population of Asian adults. Vaccine27(52), 7428–7435 (2009).
   PubMed Web of Science ®Google Scholar
• Rumke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine26(19), 2378–2388 (2008).
   PubMed Web of Science ®Google Scholar
• Newmark HL. Squalene, olive oil, and cancer risk. Review and hypothesis. Ann. NY Acad. Sci.889, 193–203 (1999).
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, LaBarbara A et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol.31(10), 2910–2918 (2001).
   PubMed Web of Science ®Google Scholar
• Alving CR, Grabenstein JD. Re: antibodies to squalene in Gulf War Syndrome. Exp. Mol. Pathol.68(3), 196–198 (2000).
   PubMed Web of Science ®Google Scholar
• Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine27(29), 3921–3926 (2009).
   PubMed Web of Science ®Google Scholar
• Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur. J. Intern. Med.21(2), 70–73 (2010).
   PubMed Web of Science ®Google Scholar
• Chan K-C. Gulf War illnesses: questions about the presence of squalene antibodies in veterans can be resolved. United States General Accounting Office, Washington, DC, USA (1999).
   Google Scholar
• Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med.361(25), 2424–2435 (2009).
   PubMed Web of Science ®Google Scholar
• Global Advisory Committee on Vaccine Safety, 6–7 June 2006. Wkly Epidemiol. Rec.81(28), 273–278 (2006).
   PubMedGoogle Scholar
• Offit PA. Thimerosal and vaccines – a cautionary tale. N. Engl. J. Med.357(13), 1278–1279 (2007).
   PubMed Web of Science ®Google Scholar
• Heron J, Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics114(3), 577–583 (2004).
   PubMed Web of Science ®Google Scholar
• Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics114(3), 584–591 (2004).
   PubMed Web of Science ®Google Scholar
• Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics118(1), e139–e150 (2006).
   Web of Science ®Google Scholar
• Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N. Engl. J. Med.357(13), 1281–1292 (2007).
   PubMed Web of Science ®Google Scholar
• Yess NJ. U.S. Food and Drug Administration survey of methyl mercury in canned tuna. J. AOAC Int.76(1), 36–38 (1993).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Gentile A, Giglio N et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics121(2), e208–e214 (2008).
   PubMed Web of Science ®Google Scholar
• Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit. Rev. Toxicol.36(8), 609–662 (2006).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet360(9347), 1737–1741 (2002).
   PubMed Web of Science ®Google Scholar
• Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. Br. Med. J.339, b3680 (2009).
   Google Scholar
• Bohlke K, Davis RL, Marcy SM et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics112(4), 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Peng MM, Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch. Intern. Med.164(3), 317–319 (2004).
   PubMedGoogle Scholar
• Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–2010 influenza season: a multicentre, randomised controlled trial. Lancet375(9708), 49–55 (2010).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Schioppa F, Lattanzi M et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int. J. Clin. Pract.64(4), 432–438 (2010).
   PubMed Web of Science ®Google Scholar
• Walker WT, Andrews N, Waddington C et al. Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving 2 doses of AS03B-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines. Presented at: Options for the Control of Influenza VII. Hong Kong SAR, China, 3–7 September 2010 (p 80).
   Google Scholar
• Yung C, Andrews N, Waight P, Hoschler K, Miller E. Age-specific effectiveness and immunogenicity of an oil-in-water adjuvanted paendemic (H1N1) 2009 vaccine in high risk groups in England. Presented at: Options for the Control of Influenza VII. Hong Kong SAR, China, 3–7 September 2010 (p 75).
   Google Scholar
• Kelly H, Barr I. Large trials confirm immunogenicity of H1N1 vaccines. Lancet375(9708), 6–9 (2010).
   PubMed Web of Science ®Google Scholar
• Van Buynder PG, Dhaliwal JK, Van Buynder JL et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi. Viruses4(4), 171–178 (2010).
   PubMed Web of Science ®Google Scholar
• Wichmann O, Stocker P, Poggensee G et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro Surveill.15(18) pii: 19561 (2010).
   Google Scholar
• Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER), an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol. Assess.14(34), 313–346 (2010).
   PubMed Web of Science ®Google Scholar
• MHRA. Final public statement – UK Suspected Adverse Reaction Analysis: Swine Flu (H1N1) Vaccines – Celvapan and Pandemrix. 26 March 2010: MHRA2010 1 April 2010.
   Google Scholar
• Vesikari T. Hot topics in vaccines. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N. Engl. J. Med.362(1), 27–35 (2010).
   PubMed Web of Science ®Google Scholar
• Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet374(9688), 451–458 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen-Van-Tam JS, Openshaw PJ, Hashim A et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May–September 2009). Thorax65(7), 645–651 (2010).
   PubMed Web of Science ®Google Scholar
• Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl. J. Med.359(15), 1555–1564 (2008).
   PubMed Web of Science ®Google Scholar
• Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain–Barre syndrome. Drug Saf.32(4), 309–323 (2009).
   PubMed Web of Science ®Google Scholar
• Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain–Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol.169(3), 382–388 (2009).
   PubMed Web of Science ®Google Scholar
• Viray M, Wise M, Sejvar J et al. Active population-based surveillance among 45 million people in the US for Guillain–Barre syndrome following introduction of influenza A(H1N1) 2009 monovalent vaccination, October 2009–March 2010. Presented at: Options for the Control of Influenza VII. Hong Kong SAR, China, 3–7 September 2010 (p 76).
   Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain–Barre syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. Am. J. Epidemiol.110(2), 105–123 (1979).
   PubMed Web of Science ®Google Scholar
• MPA. Final summary of adverse drug reaction reports in Sweden with Pandemrix through October 2009–mid April 2010. Lakemedelsverket Medical Products Agency, Uppsala, Sweden (2010).
   Google Scholar
• Booy R, Brown LE, Grohmann GS, Macintyre CR. Pandemic vaccines: promises and pitfalls. Med. J. Aust.185(10 Suppl.), S62–S65 (2006).
   Google Scholar
• Johansen K, Nicoll A, Ciancio BC, Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill.14(41), 19361 (2009).
   PubMedGoogle Scholar
• ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill.14(39) pii: 19345 (2009).
   Google Scholar
• Strategic Advisory Group of Experts on Immunization – report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol. Rec.84(30), 301–304 (2009).
   PubMedGoogle Scholar
• Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J.28(7), 563–571 (2009).
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen A, Wang T et al. An influenza vaccine based on the conserved hemagglutinin stalk domain. Presented at: Options for the Control of Influenza VII. Hong Kong SAR, China, 3–7 September 2010 (p 82).
   Google Scholar
• Barr IG, McCauley J, Cox N et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine28(5), 1156–1167 (2010).
   PubMed Web of Science ®Google Scholar
• Nauta JJ, de Bruijn IA. The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals. Vaccine24(44–46), 6643–6644 (2006).
   PubMed Web of Science ®Google Scholar